Cancer Genetics Inc (NASDAQ:CGIX) COO John A. Roberts acquired 12,200 shares of the firm’s stock in a transaction on Friday, December 15th. The stock was purchased at an average price of $2.00 per share, for a total transaction of $24,400.00. Following the acquisition, the chief operating officer now directly owns 12,200 shares in the company, valued at approximately $24,400. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Cancer Genetics Inc (CGIX) traded up $0.10 during midday trading on Thursday, hitting $2.05. The stock had a trading volume of 160,300 shares, compared to its average volume of 256,601. Cancer Genetics Inc has a fifty-two week low of $1.30 and a fifty-two week high of $5.30. The company has a debt-to-equity ratio of 0.18, a quick ratio of 2.01 and a current ratio of 2.01.

CGIX has been the topic of several analyst reports. HC Wainwright reiterated a “buy” rating and set a $6.00 price target on shares of Cancer Genetics in a report on Thursday, September 21st. Maxim Group set a $6.00 price target on Cancer Genetics and gave the stock a “buy” rating in a report on Wednesday, December 13th. Zacks Investment Research upgraded Cancer Genetics from a “sell” rating to a “hold” rating in a report on Wednesday, November 29th. Finally, ValuEngine lowered Cancer Genetics from a “hold” rating to a “sell” rating in a report on Friday, September 1st. One analyst has rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating to the company’s stock. Cancer Genetics presently has a consensus rating of “Hold” and an average price target of $5.56.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Northern Trust Corp raised its holdings in shares of Cancer Genetics by 61.0% during the 2nd quarter. Northern Trust Corp now owns 32,122 shares of the medical research company’s stock worth $127,000 after acquiring an additional 12,168 shares during the period. Thompson Davis & CO. Inc. raised its holdings in shares of Cancer Genetics by 5,465.0% during the 2nd quarter. Thompson Davis & CO. Inc. now owns 111,300 shares of the medical research company’s stock worth $440,000 after acquiring an additional 109,300 shares during the period. Granahan Investment Management Inc. MA raised its holdings in shares of Cancer Genetics by 26.3% during the 3rd quarter. Granahan Investment Management Inc. MA now owns 237,431 shares of the medical research company’s stock worth $641,000 after acquiring an additional 49,371 shares during the period. Renaissance Technologies LLC raised its holdings in shares of Cancer Genetics by 44.8% during the 1st quarter. Renaissance Technologies LLC now owns 449,600 shares of the medical research company’s stock worth $1,843,000 after acquiring an additional 139,200 shares during the period. Finally, Vanguard Group Inc. increased its position in shares of Cancer Genetics by 61.9% during the 2nd quarter. Vanguard Group Inc. now owns 516,785 shares of the medical research company’s stock worth $2,041,000 after purchasing an additional 197,619 shares during the last quarter. Institutional investors and hedge funds own 11.13% of the company’s stock.

WARNING: “Cancer Genetics Inc (CGIX) COO Acquires $24,400.00 in Stock” was first reported by Watch List News and is the property of of Watch List News. If you are accessing this news story on another publication, it was illegally copied and republished in violation of U.S. and international trademark & copyright laws. The original version of this news story can be read at https://www.watchlistnews.com/cancer-genetics-inc-cgix-coo-acquires-24400-00-in-stock/1776547.html.

Cancer Genetics Company Profile

Cancer Genetics, Inc is a United States-based company, which is engaged in the field of personalized medicine. The Company offers diagnostic products and services that enable precision medicine in the field of oncology through molecular markers and diagnostics. The Company offers a range of laboratory services that provide genomic and biomarker information.

Insider Buying and Selling by Quarter for Cancer Genetics (NASDAQ:CGIX)

Receive News & Ratings for Cancer Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cancer Genetics and related companies with MarketBeat.com's FREE daily email newsletter.